Jan 7, 2026 03:46AM Piper Sandler Starts ORIC Pharmaceuticals (ORIC) at Overweight

Dec 23, 2025 05:30PM Jefferies lists 5 biotech M&A candidates for 2026

Dec 9, 2025 06:00PM This SMID biotech stock is on JPMorgan's 'Analyst Focus List'

Dec 8, 2025 05:49AM ORIC Pharmaceuticals (ORIC) PT Raised to $25 at Wells Fargo

Dec 5, 2025 06:00AM ORIC Pharmaceuticals reports 35% response rate for lung cancer drug

Dec 4, 2025 06:50AM Goldman Sachs Starts ORIC Pharmaceuticals (ORIC) at Early-Stage Biotech, 'Potential for differentiated approach in prostate cancer'

Nov 20, 2025 01:00AM Evercore ISI Starts ORIC Pharmaceuticals (ORIC) at Outperform

Nov 17, 2025 04:14PM Wolfe Research Starts ORIC Pharmaceuticals (ORIC) at Peerperform

Nov 13, 2025 06:36PM ORIC Pharmaceuticals, Inc. (ORIC) Tops Q3 EPS by 7c

Nov 6, 2025 04:00PM ORIC Pharmaceuticals publishes enozertinib research in Cancer Research

Sep 26, 2025 06:42AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)

Sep 4, 2025 05:42AM Guggenheim Assumes ORIC Pharmaceuticals (ORIC) at Buy

Aug 18, 2025 04:06PM ORIC Pharmaceuticals names Kevin Brodbeck as chief technical officer

Aug 13, 2025 05:44AM ORIC Pharmaceuticals (ORIC) PT Raised to $23 at Jefferies

Aug 12, 2025 05:55PM ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 3c

Jul 8, 2025 07:33AM Ladenburg Thalmann Starts ORIC Pharmaceuticals (ORIC) at Buy

Jun 3, 2025 07:04AM H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)

May 29, 2025 06:42AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)

May 29, 2025 06:20AM Cantor Fitzgerald on ORIC Pharmaceuticals (ORIC): 'Solid Update in Prostate Cancer for ORIC-944'

May 28, 2025 04:09PM ORIC Pharmaceuticals Inc. (ORIC) Announces $125 Million Private Placement at $6.50/sh

May 21, 2025 10:08AM ORIC Pharmaceuticals Inc. (ORIC) Shares Continue Strength Follow Y'Day Sell side Comments, +6pct

May 20, 2025 10:16AM JPMorgan on ORIC Pharamceuticals (ORIC): 'Top Pick', 'ORIC shares should be ~2-4X current levels', PT $20

May 20, 2025 09:59AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)

May 9, 2025 07:02AM ORIC Pharamceuticals (ORIC) PT Raised to $22 at H.C. Wainwright

May 5, 2025 08:48PM ORIC Pharmaceuticals, Inc. (ORIC) Tops Q1 EPS by 9c

Apr 28, 2025 04:30PM ORIC Pharmaceuticals Inc. (ORIC) Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer

Mar 7, 2025 04:48PM ORIC Pharmaceuticals announces inducement grants to three employees

Feb 18, 2025 07:23AM Stifel Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)

Feb 11, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)

Feb 10, 2025 03:58PM Jones Trading Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)

Feb 10, 2025 11:12AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC) Following Possible ASCO-GU Feb 13 News Title Leak

Feb 10, 2025 11:11AM Cantor Says Buy ORIC Pharmaceuticals Inc. (ORIC) Shares On Possible Mevro Data Leak

Feb 4, 2025 09:38AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)

Feb 4, 2025 04:58AM Citi Opens 30-Day Upside Catalyst Call on ORIC Pharamceuticals (ORIC)

Jan 13, 2025 08:06AM ORIC Pharmaceuticals Inc. (ORIC) Provides Early Phase 1b Combination Data for ORIC-944

Nov 12, 2024 04:21PM ORIC Pharmaceuticals, Inc. (ORIC) Misses Q3 EPS by 1c

Oct 30, 2024 04:29PM Jones Trading Starts ORIC Pharamceuticals (ORIC) at Buy

Oct 23, 2024 07:01AM ORIC Pharmaceuticals Inc. (ORIC) Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations

Sep 19, 2024 06:46AM H.C. Wainwright Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)

Sep 5, 2024 04:08PM Stifel Starts ORIC Pharamceuticals (ORIC) at Buy

Aug 13, 2024 07:50AM ORIC Pharamceuticals (ORIC) PT Lowered to $15 at Oppenheimer

Aug 12, 2024 04:56PM ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 4c

Jul 16, 2024 04:59PM ORIC Pharma (ORIC) Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cance